Vandervoort Adam C 4

What Happened Adam C. Vandervoort, Teladoc Health’s Chief Legal Officer and Secretary, had restricted and performance awards convert into 14,928 shares on June 1, 2026 (three conversion/exercise entries: 426, 5,350 and 9,152 shares). Following conversion, 7,906 shares were sold in an open‑market transaction on June 2, 2026 at $7.63 per share for gross proceeds of $60,299. The filing shows certain shares were treated as derivative dispositions at $0 — consistent with shares being used to satisfy tax withholding or otherwise retained/withheld in connection with the vesting/conversion.

Key Details

• Transaction dates: conversions/exercises on 2026-06-01; open‑market sale on 2026-06-02.
• Sale: 7,906 shares at $7.63 for $60,299 total.
• Converted/received: 14,928 shares (426 + 5,350 + 9,152) on 2026-06-01.
• Shares shown as disposed at $0 reflect withholding/transfer in connection with conversion/vesting (per footnote).
• Footnotes: F1/F2 – PSUs and RSUs convert 1:1 to TDOC common stock. F3 – shares sold to cover tax withholding related to vesting. F4–F7 describe vesting schedules/grants underlying the awards (including PSU earned 3/1/2026 and RSU grants from 3/19/2024 and 3/1/2025).
• Shares owned after the transaction are not disclosed in the filing.
• Filing date: 2026-06-03 (timely; Form 4 filed within the normal two-business-day window).

Context

• The M transaction code indicates exercise/conversion of derivative awards (here, PSUs/RSUs converting to common shares). The subsequent open‑market sale appears primarily to cover tax withholding obligations tied to the vesting/conversion (a common, routine action), rather than a standalone investment judgment. This filing does not necessarily indicate a broader change in insider sentiment.